Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Vaccines in development against West Nile virus.

Brandler S, Tangy F.

Viruses. 2013 Sep 30;5(10):2384-409. doi: 10.3390/v5102384. Review.

2.

Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis.

Desprès P, Combredet C, Frenkiel MP, Lorin C, Brahic M, Tangy F.

J Infect Dis. 2005 Jan 15;191(2):207-14. Epub 2004 Dec 10.

PMID:
15609230
3.

Technologies for the development of West Nile virus vaccines.

Ulbert S, Magnusson SE.

Future Microbiol. 2014;9(10):1221-32. doi: 10.2217/fmb.14.67. Review.

4.

Measles vaccine expressing the secreted form of West Nile virus envelope glycoprotein induces protective immunity in squirrel monkeys, a new model of West Nile virus infection.

Brandler S, Marianneau P, Loth P, Lacôte S, Combredet C, Frenkiel MP, Desprès P, Contamin H, Tangy F.

J Infect Dis. 2012 Jul 15;206(2):212-9. doi: 10.1093/infdis/jis328. Epub 2012 May 2.

PMID:
22551814
5.

Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens.

Volz A, Lim S, Kaserer M, Lülf A, Marr L, Jany S, Deeg CA, Pijlman GP, Koraka P, Osterhaus AD, Martina BE, Sutter G.

Vaccine. 2016 Apr 7;34(16):1915-26. doi: 10.1016/j.vaccine.2016.02.042. Epub 2016 Mar 2.

PMID:
26939903
6.

Efficacy, duration, and onset of immunogenicity of a West Nile virus vaccine, live Flavivirus chimera, in horses with a clinical disease challenge model.

Long MT, Gibbs EP, Mellencamp MW, Bowen RA, Seino KK, Zhang S, Beachboard SE, Humphrey PP.

Equine Vet J. 2007 Nov;39(6):491-7.

PMID:
18065305
7.

Safety of an attenuated West Nile virus vaccine, live Flavivirus chimera in horses.

Long MT, Gibbs EP, Mellencamp MW, Zhang S, Barnett DC, Seino KK, Beachboard SE, Humphrey PP.

Equine Vet J. 2007 Nov;39(6):486-90.

PMID:
18065304
8.

Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine.

Maximova OA, Speicher JM, Skinner JR, Murphy BR, St Claire MC, Ragland DR, Herbert RL, Pare DR, Moore RM, Pletnev AG.

Vaccine. 2014 May 30;32(26):3187-97. doi: 10.1016/j.vaccine.2014.04.002. Epub 2014 Apr 13.

9.

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.

Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J.

Vaccine. 2010 Jan 8;28(3):632-49. doi: 10.1016/j.vaccine.2009.09.098. Epub 2009 Oct 4. Review.

PMID:
19808029
10.

A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice.

Spohn G, Jennings GT, Martina BE, Keller I, Beck M, Pumpens P, Osterhaus AD, Bachmann MF.

Virol J. 2010 Jul 6;7:146. doi: 10.1186/1743-422X-7-146.

11.

Development of chimaeric West Nile virus attenuated vaccine candidate based on the Japanese encephalitis vaccine strain SA14-14-2.

Li XF, Zhao W, Lin F, Ye Q, Wang HJ, Yang D, Li SH, Zhao H, Xu YP, Ma J, Deng YQ, Zhang Y, Qin ED, Qin CF.

J Gen Virol. 2013 Dec;94(Pt 12):2700-9. doi: 10.1099/vir.0.059436-0. Epub 2013 Oct 3.

PMID:
24092759
12.

Repeated in vivo stimulation of T and B cell responses in old mice generates protective immunity against lethal West Nile virus encephalitis.

Uhrlaub JL, Brien JD, Widman DG, Mason PW, Nikolich-Zugich J.

J Immunol. 2011 Apr 1;186(7):3882-91. doi: 10.4049/jimmunol.1002799. Epub 2011 Feb 21.

13.

Prospects for development of a vaccine against the West Nile virus.

Monath TP.

Ann N Y Acad Sci. 2001 Dec;951:1-12. Review.

PMID:
11797767
14.

Yellow fever vector live-virus vaccines: West Nile virus vaccine development.

Arroyo J, Miller CA, Catalan J, Monath TP.

Trends Mol Med. 2001 Aug;7(8):350-4. Review.

PMID:
11516995
15.

Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge.

De Filette M, Soehle S, Ulbert S, Richner J, Diamond MS, Sinigaglia A, Barzon L, Roels S, Lisziewicz J, Lorincz O, Sanders NN.

PLoS One. 2014 Feb 4;9(2):e87837. doi: 10.1371/journal.pone.0087837. eCollection 2014. Erratum in: PLoS One. 2014;9(2):e91631.

16.

West Nile virus vaccines.

Hall RA, Khromykh AA.

Expert Opin Biol Ther. 2004 Aug;4(8):1295-305.

PMID:
15268663
17.

Inactivated West Nile Virus (WNV) vaccine, Duvaxyn WNV, protects against a highly neuroinvasive lineage 2 WNV strain in mice.

Venter M, van Vuren PJ, Mentoor J, Paweska J, Williams J.

Vaccine. 2013 Aug 20;31(37):3856-62. doi: 10.1016/j.vaccine.2013.06.059. Epub 2013 Jun 29.

PMID:
23820079
18.

A review of vaccine approaches for West Nile virus.

Iyer AV, Kousoulas KG.

Int J Environ Res Public Health. 2013 Sep 10;10(9):4200-23. doi: 10.3390/ijerph10094200. Review.

19.

West Nile virus vaccine.

Monath TP, Arroyo J, Miller C, Guirakhoo F.

Curr Drug Targets Infect Disord. 2001 May;1(1):37-50. Review.

PMID:
12455232
20.

[West Nile fever/encephalitis].

Takasaki T.

Uirusu. 2007 Dec;57(2):199-205. Review. Japanese.

Supplemental Content

Support Center